Heron Therapeutics Inc (NASDAQ: HRTX) on Tuesday, plunged -4.48% from the previous trading day, before settling in for the closing price of $1.34. Within the past 52 weeks, HRTX’s price has moved between $1.00 and $2.68.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 48.68%. The company achieved an average annual earnings per share of -11.11%. With a float of $181.64 million, this company’s outstanding shares have now reached $183.32 million.
Considering the fact that the conglomerate employs 122 people, you should pay attention to its efficiency factor.
Heron Therapeutics Inc (HRTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Heron Therapeutics Inc is 0.94%, while institutional ownership is 83.72%. The most recent insider transaction that took place on Aug 08 ’25, was worth 3,580,838. In this transaction 10% Owner of this company bought 2,387,225 shares at a rate of $1.50, taking the stock ownership to the 29,100,728 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Director bought 1,766,546 for $1.50, making the entire transaction worth $2,649,819. This insider now owns 8,753,290 shares in total.
Heron Therapeutics Inc (HRTX) Recent Fiscal highlights
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported 0.02 earnings per share (EPS) for the period topping the consensus outlook (set at -0.03) by 0.05.
According to the Wall Street analysts, stocks earnings will be around -11.11% per share during the next fiscal year.
Heron Therapeutics Inc (NASDAQ: HRTX) Trading Performance Indicators
Heron Therapeutics Inc (HRTX) is currently performing well based on its current performance indicators. A quick ratio of 1.78 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.08, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.00 in one year’s time.
Technical Analysis of Heron Therapeutics Inc (HRTX)
Compared to the last year’s volume of 1.73 million, its volume of 2.13 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 56.55%.
During the past 100 days, Heron Therapeutics Inc’s (HRTX) raw stochastic average was set at 32.01%, which indicates a significant decrease from 47.87% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0900 in the past 14 days, which was higher than the 0.0753 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.2145, while its 200-day Moving Average is $1.6793. Nevertheless, the first resistance level for the watch stands at $1.3233 in the near term. At $1.3667, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.3933. If the price goes on to break the first support level at $1.2533, it is likely to go to the next support level at $1.2267. Now, if the price goes above the second support level, the third support stands at $1.1833.
Heron Therapeutics Inc (NASDAQ: HRTX) Key Stats
Market capitalization of the company is 234.71 million based on 183,363K outstanding shares. Right now, sales total 144,290 K and income totals -13,580 K. The company made 38,210 K in profit during its latest quarter, and -17,500 K in sales during its previous quarter.
